Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities
Rhea-AI Summary
Neurocrine Biosciences (Nasdaq: NBIX) reported clinician-reported data on INGREZZA (valbenazine) in 30 individuals with tardive dyskinesia and intellectual and developmental disabilities.
Nearly all showed reduced TD severity; 89% improved within four weeks, with broad gains in functional, physical, and socio-emotional outcomes, including independence, emotions, socializing, dexterity, and speech.
AI-generated analysis. Not financial advice.
Positive
- Clinician-reported TD improvements in nearly all 30 individuals with intellectual and developmental disabilities
- 89% (25/28) showed reduced TD symptoms within four weeks of starting INGREZZA
- Overall functional status improved in 96% of participants with impaired function
- Posttreatment improvements: socializing 92%, dexterity 91%, emotions 85%, independence 83%
- Speech improved in 100% of patients whose speech was negatively impacted at baseline
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
NBIX is down 2.07% while close peers show mixed, mostly modest moves (e.g., UTHR +0.51%, TAK +0.58%, TEVA -0.32%, RDY -0.53%, VTRS +0.06%). This points to stock-specific trading rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-06-03 | Clinical data previews | Positive | +6.6% | Announcement of new two‑year CRENESSITY analyses to be presented at ENDO 2026. |
| 2026-05-26 | Investor conferences | Neutral | +0.1% | Planned participation in June investor conferences with executive fireside chats and webcasts. |
| 2026-05-18 | Real‑world TD data | Positive | -2.2% | Real‑world clinician survey showing functional gains with INGREZZA in mild TD at APA 2026. |
| 2026-05-18 | Soleno acquisition | Positive | -0.8% | Completion of all‑cash, $2.9 billion Soleno deal adding VYKAT XR for Prader‑Willi. |
| 2026-05-06 | Dosing guidance | Positive | +8.9% | Publication of expert algorithms for glucocorticoid dose reduction with CRENESSITY in CAH. |
NBIX’s scientific and clinical communication has often been met with positive reactions, but recent tardive dyskinesia real-world data on INGREZZA saw a negative move, indicating that similar positive TD updates do not always translate into near-term gains.
Over the past month, NBIX has highlighted multiple clinical and real-world data sets and executed a sizable acquisition. On May 6, guidance on CRENESSITY® dosing coincided with a +8.86% move. Two TD‑related INGREZZA updates on May 18 produced mixed trading, including a -2.18% reaction to positive real‑world data. The $2.9 billion Soleno deal on May 18 and new CRENESSITY analyses announced on June 3 also frame today’s additional INGREZZA data within an active R&D and business development period.
Market Pulse Summary
This announcement extends real‑world evidence for INGREZZA in a challenging tardive dyskinesia population with intellectual and developmental disabilities, showing rapid improvement for 89% of patients within four weeks and better overall function in 96% of those impaired at baseline. In recent months NBIX has paired such data with broader pipeline and business moves, including CRENESSITY dosing guidance and the Soleno acquisition. Investors may watch how ongoing real‑world and long‑term datasets influence INGREZZA’s positioning in a competitive TD landscape.
Key Terms
tardive dyskinesia medical
valbenazine medical
antipsychotic medical
AI-generated analysis. Not financial advice.
- Nearly all individuals with intellectual and developmental disabilities experienced improvement in tardive dyskinesia severity after starting INGREZZA, and of those,
89% experienced improvement within 4 weeks - Clinician-reported data showed improvements in key aspects of daily life following INGREZZA treatment in nearly all patients with tardive dyskinesia and intellectual and developmental disabilities who had impaired function
These data highlight the significant burden associated with tardive dyskinesia (TD) in individuals with intellectual and developmental disabilities, as well as the rapid clinician-reported improvements seen in TD movements following treatment with INGREZZA. Clinicians also observed functional gains across multiple areas of daily living, including social and emotional well-being, communication abilities and motor skills, such as hand coordination.
"People with intellectual and developmental disabilities are at increased risk for tardive dyskinesia due to long-term antipsychotic use, yet the condition often goes underdiagnosed and its impact underrecognized," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "The clinician-reported improvements observed in this analysis complement patient-reported outcomes from the KINECT-PRO study, further highlighting the potential of INGREZZA to make a meaningful difference in areas that matter most to people living with tardive dyskinesia. This analysis, which is the first and only of its kind, also reflects our ongoing commitment to advancing studies that better represent and serve the diverse populations affected by the condition."
This analysis was based on clinician‑reported data from patients who initiated INGREZZA between January and June 2024, completed at least two months of treatment and had at least one follow‑up visit, including a subgroup of 30 individuals with reported intellectual and developmental disabilities (mean age: 47.3 years; standard deviation: 14.6). The most common psychiatric comorbidities in this subgroup were schizophrenia (
Nearly all individuals experienced reductions in TD symptoms, with
Outcome | Baseline: % Patients | Posttreatment: % Patients |
Overall functional status | 90 % | 96 % |
Independence | 90 % | 83 % |
Emotions | 90 % | 85 % |
Socializing with family and friends | 83 % | 92 % |
Dexterity | 73 % | 91 % |
Speech | 53 % | 100 % |
*Percentage improved among patients who were negatively impacted at baseline | ||
A previous publication examined the use of INGREZZA in five adults with mild to severe intellectual and developmental disabilities and TD. Following treatment with INGREZZA, patients experienced reduced TD movements, accompanied by improvements in daily functioning, demeanor and social and caregiver interactions. The present analysis extends those findings, emphasizing the need to recognize the burden of TD beyond uncontrolled movements, including functional and socio-emotional outcomes that are especially meaningful for patients with intellectual and development disabilities, as well as their families and care partners.
Additional presentation at the American Academy of Developmental Medicine and Dentistry's 24th Annual Education Conference included:
- Use and Misuse of Anticholinergics for Drug Induced Movement Disorders
About Tardive Dyskinesia
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be mild to severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S.
About the KINECT-PRO™ Phase 4 Study
The KINECT-PRO™ Phase 4, open-label study was designed to evaluate patient-reported outcomes on the use of INGREZZA® (valbenazine) capsules in a tardive dyskinesia (TD) patient population reflective of real-world clinical practice. Participants had at least mild TD, were aware of and experiencing at least mild distress from their abnormal, involuntary movements and had a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or major depression. The KINECT-PRO study included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic and clinical characteristics of the participants were broadly similar to those of the KINECT® 3 and KINECT® 4 studies.
KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale (TDIS™). The TDIS is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition.
About INGREZZA® (valbenazine) Capsules and INGREZZA® SPRINKLE (valbenazine) Capsules
INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA offers a therapeutic dose from day one with no required titration.
INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA is unique in that it selectively and specifically targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements.
INGREZZA is studied across the widest range of patients. It is always one capsule, once daily and can be taken together with most stable mental health regimens such as antipsychotics or antidepressants. Only INGREZZA offers the benefit of a sprinkle formulation, INGREZZA SPRINKLE, for those who experience dysphagia, have difficulty swallowing or prefer not to swallow a pill. INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg and 80 mg capsules.
Important Information
Approved Uses
INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with:
- movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
- involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions.
It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children.
IMPORTANT SAFETY INFORMATION
INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself.
Do not take INGREZZA or INGREZZA SPRINKLE if you:
- are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE.
INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including:
- Allergic reactions. Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema.
- Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation). Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE.
- Heart rhythm problems (QT prolongation). INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow, or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint.
- Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating, or very fast or uneven heartbeat.
- Parkinson-like symptoms. Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors), or falls.
Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days.
The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia are sleepiness and tiredness.
The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep.
These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules.
Please see full Prescribing Information, including Boxed Warning, and Medication Guide.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, INGREZZA and KINECT are registered trademarks of Neurocrine Biosciences, Inc. KINECT-PRO and TDIS are trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA, the interpretation and potential relevance of the data described in this press release, including statements regarding improvements in patients' functional status and physical and socio-emotional outcomes following treatment with INGREZZA, and the other value INGREZZA may bring to patients. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of INGREZZA; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA; whether INGREZZA receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA; risks that post-approval INGREZZA commitments or requirements may be delayed; risks that INGREZZA may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.
© 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-VBZ-US-0103 06/2026
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-data-highlighting-functional-and-socio-emotional-improvements-with-ingrezza-valbenazine-capsules-in-individuals-with-tardive-dyskinesia-and-intellectual-and-developmental-disabilities-302793148.html
SOURCE Neurocrine Biosciences, Inc.